title: Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
abstract: A wealth of evidence has led to the conclusion that virtually all cases of cervical cancer are attributable to persistent infection by a subset of human papillomavirus (HPV) types, especially HPV type 16 (HPV-16) and HPV-18. These HPV types also cause a proportion of other cancers, including vulvar, vaginal, anal, penile, and oropharyngeal cancers. Although cervical cancer screening, primarily with the Papanicolaou (Pap) smear, has reduced the incidence of this cancer in industrialized countries, cervical cancer remains the second most common cause of death from cancer in women worldwide, because the developing world has lacked the resources for widespread, high-quality screening. In addition to advances in Pap smear technology, the identification of HPV as the etiologic agent has produced 2 recent advances that may have a major impact on approaches to reduce the incidence of this disease. The first is the development of a preventive vaccine, the current versions of which appear to prevent close to 100% of persistent genital infection and disease caused by HPV-16 and HPV-18; future second-generation vaccines may be able to protect against oncogenic infections by a broader array of HPV types. The second is the incorporation of HPV testing into screening programs. In women aged >30 years, HPV testing can identify high-grade cervical intraepithelial neoplasia earlier than Pap smears with acceptable rates of specificity. These results, together with the high sensitivity of HPV testing, suggest that such testing could permit increased intervals for screening. An inexpensive HPV test in development, if successful, may be incorporated as part of an economically viable 'screen-and-treat' approach in the developing world. The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer.
authors.affiliation: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. lowyd@mail.nih.gov
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Lowy
authors.forename: Diane
authors.initials: D
authors.lastname: Solomon
authors.forename: Allan
authors.initials: A
authors.lastname: Hildesheim
authors.forename: John T
authors.initials: JT
authors.lastname: Schiller
authors.forename: Mark
authors.initials: M
authors.lastname: Schiffman
mesh_terms: D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics; D052161:Human papillomavirus 18 / Q000235:genetics; D006801:Humans; D009857:Oncogenes; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000150:complications*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000517:prevention & control*; D014611:Vaccination; D014626:Vaginal Smears
chemical_list: D053918:Papillomavirus Vaccines
references.citation: N Engl J Med. 2007 Oct 18;357(16):1579-88
references.pmid: 17942871
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28
references.pmid: 17237032
references.citation: Br J Cancer. 2008 Jan 15;98(1):15-21
references.pmid: 18182975
references.citation: J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
references.pmid: 18364507
references.citation: Lancet. 2007 Jun 2;369(9576):1861-1868
references.pmid: 17544766
references.citation: Lancet. 2007 Nov 24;370(9601):1740-2
references.pmid: 17919717
references.citation: Am J Obstet Gynecol. 2007 Oct;197(4):356.e1-6
references.pmid: 17904958
references.citation: Int J Gynaecol Obstet. 2008 Jan;100(1):24-6
references.pmid: 17897647
references.citation: Int J Cancer. 2004 Aug 20;111(2):278-85
references.pmid: 15197783
references.citation: Virology. 2004 Apr 10;321(2):205-16
references.pmid: 15051381
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33
references.pmid: 16492924
references.citation: N Engl J Med. 2007 May 10;356(19):1928-43
references.pmid: 17494926
references.citation: Am J Obstet Gynecol. 2007 Jul;197(1):47.e1-8
references.pmid: 17618753
references.citation: Am J Obstet Gynecol. 2007 Oct;197(4):340-5
references.pmid: 17904956
references.citation: J Virol. 1996 May;70(5):3298-301
references.pmid: 8627814
references.citation: J Infect Dis. 2005 Jun 1;191(11):1796-807
references.pmid: 15871111
references.citation: Lancet. 2007 Nov 24;370(9601):1764-72
references.pmid: 17919718
references.citation: Int J Gynaecol Obstet. 2003 Dec;83(3):311-3
references.pmid: 14643047
references.citation: Obstet Gynecol. 2007 Oct;110(4):833-40
references.pmid: 17906017
references.citation: J Cancer Res Clin Oncol. 2007 Apr;133(4):235-45
references.pmid: 17294241
references.citation: N Engl J Med. 2006 Jun 22;354(25):2645-54
references.pmid: 16790697
references.citation: Front Biosci. 2008 Jan 01;13:1003-17
references.pmid: 17981607
references.citation: Int J Cancer. 2006 Dec 1;119(11):2677-84
references.pmid: 16991121
references.citation: J Natl Cancer Inst Monogr. 2003;(31):41-6
references.pmid: 12807944
references.citation: Cancer Res. 2006 Oct 15;66(20):10112-9
references.pmid: 17047075
references.citation: Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S7-11
references.pmid: 16154623
references.citation: Am J Obstet Gynecol. 2006 Aug;195(2):349-53
references.pmid: 16677597
references.citation: J Biol Chem. 2007 Oct 26;282(43):31803-11
references.pmid: 17804402
references.citation: Annu Rev Immunol. 1997;15:235-70
references.pmid: 9143688
references.citation: J Virol. 1991 Feb;65(2):606-12
references.pmid: 1846186
references.citation: J Natl Cancer Inst Monogr. 2003;(31):97-101
references.pmid: 12807952
references.citation: Lancet Oncol. 2006 Jul;7(7):547-55
references.pmid: 16814206
references.citation: N Engl J Med. 2002 Apr 11;346(15):1105-12
references.pmid: 11948269
references.citation: Cancer Res. 2008 Jan 1;68(1):307-13
references.pmid: 18172324
references.citation: BMC Womens Health. 2007 Oct 01;7:16
references.pmid: 17908317
references.citation: Am J Obstet Gynecol. 2007 Oct;197(4):346-55
references.pmid: 17904957
references.citation: J Gen Virol. 2007 May;88(Pt 5):1460-1469
references.pmid: 17412974
references.citation: Am J Clin Pathol. 2005 Feb;123(2):281-7
references.pmid: 15842055
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89
references.pmid: 16950021
references.citation: N Engl J Med. 2007 Oct 18;357(16):1589-97
references.pmid: 17942872
references.citation: Br J Cancer. 1999 Aug;80(12):2008-18
references.pmid: 10471054
references.citation: Lancet. 2007 Sep 8;370(9590):890-907
references.pmid: 17826171
references.citation: Clin Cancer Res. 2007 May 1;13(9):2599-605
references.pmid: 17473189
references.citation: J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
references.pmid: 16030305
references.citation: J Natl Cancer Inst. 2006 Jun 7;98(11):765-74
references.pmid: 16757701
references.citation: J Virol. 1998 Jul;72(7):6151-4
references.pmid: 9621080
references.citation: J Infect Dis. 2007 Jun 1;195(11):1582-9
references.pmid: 17471427
references.citation: J Clin Invest. 2006 May;116(5):1167-73
references.pmid: 16670757
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7
references.pmid: 16844268
references.citation: Lancet. 2001 Jun 9;357(9271):1831-6
references.pmid: 11410191
references.citation: N Engl J Med. 2005 Nov 17;353(20):2158-68
references.pmid: 16291985
references.citation: Virology. 2005 Jun 20;337(1):76-84
references.pmid: 15914222
references.citation: Int J Cancer. 2006 Sep 1;119(5):1108-24
references.pmid: 16570271
references.citation: Virology. 2004 Jun 20;324(1):17-27
references.pmid: 15183049
references.citation: Lancet. 2007 Jun 30;369(9580):2161-2170
references.pmid: 17602732
references.citation: J Virol. 1992 Apr;66(4):2057-66
references.pmid: 1312620
references.citation: Am J Obstet Gynecol. 2003 Jun;188(6):1383-92
references.pmid: 12824967
references.citation: Int J Cancer. 2006 Mar 15;118(6):1481-95
references.pmid: 16206285
references.citation: Obstet Gynecol. 2008 Jan;111(1):167-77
references.pmid: 18165406
references.citation: Cancer. 2007 Jun 25;111(3):145-53
references.pmid: 17487850
references.citation: Virology. 2000 May 10;270(2):254-7
references.pmid: 10792983
references.citation: Lancet. 2007 May 19;369(9574):1693-702
references.pmid: 17512854
references.citation: JAMA. 2001 Mar 21;285(11):1500-5
references.pmid: 11255427
references.citation: Lancet. 2007 Aug 4;370(9585):398-406
references.pmid: 17679017
references.citation: Clin Vaccine Immunol. 2007 Oct;14(10):1285-95
references.pmid: 17687110
references.citation: Br J Cancer. 2006 Dec 4;95(11):1459-66
references.pmid: 17117182
references.citation: Lancet. 2006 Apr 15;367(9518):1247-55
references.pmid: 16631880
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/147-53
references.pmid: 16950002
references.citation: Lancet Infect Dis. 2002 Jul;2(7):395-403
references.pmid: 12127351
references.citation: Int J Cancer. 2007 Aug 1;121(3):621-32
references.pmid: 17405118
references.citation: Cancer. 2005 Oct 25;105(5):253-62
references.pmid: 15991244
references.citation: J Virol. 2007 Nov;81(21):11585-92
references.pmid: 17715230
references.citation: Sex Transm Dis. 2004 Oct;31(10):601-7
references.pmid: 15388997
references.citation: Dis Markers. 2007;23(4):315-30
references.pmid: 17627065
references.citation: Virology. 1996 May 1;219(1):37-44
references.pmid: 8623552
references.citation: Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8
references.pmid: 7878034
references.citation: Nat Rev Cancer. 2002 May;2(5):342-50
references.pmid: 12044010
references.citation: N Engl J Med. 2002 Nov 21;347(21):1652-61
references.pmid: 12444179
references.citation: Adv Data. 2005 Sep 15;(362):1-55
references.pmid: 16250464
references.citation: Virology. 2005 Jul 5;337(2):365-72
references.pmid: 15885736
references.citation: J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14
references.pmid: 12237286
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10
references.pmid: 17220325
references.citation: J Virol. 2001 Sep;75(17):7848-53
references.pmid: 11483728
references.citation: Int J Cancer. 2006 Jun 15;118(12):3030-44
references.pmid: 16404738
references.citation: Int J Cancer. 2007 Feb 15;120(4):885-91
references.pmid: 17131323
references.citation: Vaccine. 2005 May 25;23(28):3634-41
references.pmid: 15882523
references.citation: J Pathol. 2006 Jan;208(2):152-64
references.pmid: 16362994
references.citation: JAMA. 2007 Aug 15;298(7):743-53
references.pmid: 17699008
references.citation: Annu Rev Immunol. 2003;21:515-46
references.pmid: 12500980
references.citation: J Virol. 2004 Nov;78(21):11451-60
references.pmid: 15479788
references.citation: Lancet. 2003 Dec 6;362(9399):1871-6
references.pmid: 14667741
references.citation: Clin Cancer Res. 2004 May 1;10(9):3059-63
references.pmid: 15131043
references.citation: J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
references.pmid: 15753008
references.citation: J Infect Dis. 2007 Oct 15;196(8):1137-45
references.pmid: 17955431
references.citation: N Engl J Med. 2005 Nov 17;353(20):2101-4
references.pmid: 16291978
references.citation: Virology. 2000 Feb 15;267(2):141-50
references.pmid: 10662610
references.citation: Lancet. 2006 Jan 14;367(9505):122-32
references.pmid: 16413876
references.citation: Virology. 1995 Aug 1;211(1):204-8
references.pmid: 7544045
references.citation: J Infect Dis. 1995 Jun;171(6):1387-98
references.pmid: 7769272
references.citation: N Engl J Med. 2007 May 10;356(19):1915-27
references.pmid: 17494925
references.citation: Br J Cancer. 2007 Feb 12;96(3):514-8
references.pmid: 17245341
references.citation: Obstet Gynecol. 2006 Aug;108(2):264-72
references.pmid: 16880294